Thalidomide Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Thalidomide is an immunomodulatory drug and a prototype of the thalidomide class of drugs. It is mainly used in the treatment of certain cancers (multiple myeloma) and of a complication of leprosy. It is sold under the brand name Immunoprin. It has many applications in the field of medicine. The bacterium that causes tuberculosis is related to leprosy and thalidomide may be helpful in some cases where standard TB drugs and corticosteroids are not able to resolve severe inflammation in the brain. The combination of thalidomide and dexamethasone for the treatment of multiple myeloma was approved by the U.S. Food and Drug Administration in 2006.
Request for Sample Copy of Research Report: https://www.worldwidemarketreports.com/sample/157663
Increasing drug and alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, presence of government funding in major markets, regulatory approvals, and product launches and services are some of the major factors driving growth of thalidomide market.
The adverse effects such as birth defects, blood clots, several cardiovascular adverse effects, liver damage, and prevention of menstruation are some of the major factors that are expected to restrain growth of thalidomide market.
Request for Discount @ https://www.worldwidemarketreports.com/discount/157663
Key Developments in Thalidomide Market
Key players in the market are adopting strategies such as mergers, acquisitions, and new product launches to retain its position in the thalidomide market. On April 19, 2018, Pfizer’s collaboration with Asembia was expanded. Moreover, on April 3, 2018, Pfizer partnered with Allogene Therapeutics to expand the immuno oncology portfolios of Pfizer through continued development of Allogene’s CAR T therapies. On March 20, 2018, Casi Pharmaceuticals announced US$ 50 Mn private placement to prepare the company for commercialization in China.
Acceleron hosted Educational Webinar with leading clinicians to provide an overview of pulmonary arterial hypertension and the Sotatercept Phase 2 trial in March 2018. Moreover, bluebird bio and Celgene Corporation signed an agreement to co-develop and co-promote anti-BCMA CAR T cell therapy bb2121 in the U.S. On April 13, 2018, Allergan announced the launch of TrueTear® Intranasal Neurostimulation Device.
Some of the key players in the thalidomide market include Pfizer, Allergan, Alnylam Pharmaceuticals, Five Prime Therapeutics, Angstrom Pharmaceuticals, Acceleron Pharma, Biocon, Enzon Pharmaceuticals, Casi Pharmaceuticals, and Celgene Corporation.
Request for Table of Content :https://www.worldwidemarketreports.com/toc/157663
** If you have any special requirements, please let us know and we will offer you the report as you want.
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.
Worldwide Market Reports
1001 4th Ave,
Seattle, WA 98154,
Tel: +1 415 871 0703
Visit our website for more details:https://www.worldwidemarketreports.com
Visit our new website for latest News:https://www.industrychronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thalidomide Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 here
News-ID: 1221860 • Views: 660
More Releases from Pharma & Healthcare Industry
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Rx Medical Food Trends Estimates High Demand by 2024
Medical food is a category of products for dietary management or supportive therapy for specific disease or medical conditions such as pulmonary and metabolic disorders. Ingredients used in medical foods must have generally recognized as safe (GRAS) status, which is assigned to naturally found food materials. Medical food is different from nutritional food, dietary supplements, and prescription drugs. Medical food is protein-based, nutrient-based (Omega 3 fatty acids, chelated zinc, and
Specialty CRO's Market - Regional Insights
On the basis of geography, global specialty CROs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the market over the forecast period, owing to the fact that pharmaceutical and biotech companies in this region spends significant amount on research and development, in order to bring novel therapies to the market. Click To Continue Reading; https://www.coherentmarketinsights.com/ongoing-insight/specialty-cros-market-1627 As per the estimation
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,
More Releases for Thalidomide
Thalidomide Market Share Analysis 2019 | Celgene
The research study offers powerful guidelines for market players to compete well against other participants operating in the global Thalidomide market. It brings to light crucial market dynamics including drivers, challenges, restraints, trends, and opportunities. Readers are provided with detailed qualitative and quantitative analysis, PESTLE analysis, absolute dollar opportunity analysis, and Porter’s Five Forces analysis that focus on various aspects of the global Thalidomide Market. The report includes regional growth
Thalidomide Market - Global Industry Insights, Trends, Outlook, and Opportunity …
Thalidomide is an immunomodulatory drug and a prototype of the thalidomide class of drugs. It is mainly used in the treatment of certain cancers (multiple myeloma) and of a complication of leprosy. It is sold under the brand name Immunoprin. It has many applications in the field of medicine. The bacterium that causes tuberculosis is related to leprosy and thalidomide may be helpful in some cases where standard TB drugs
Thalidomide Market Analysis By Market Size, Share, Growth and Forecast up to 202 …
Worldwide Market Reports added Latest Research Report titled "Global Thalidomide Market by Manufacturers, Regions, Product Type and Application, Forecast to 2026" to its Large Report database. Thalidomide is an immunomodulatory drug and a prototype of the thalidomide class of drugs. It is mainly used in the treatment of certain cancers (multiple myeloma) and of a complication of leprosy. It is sold under the brand name Immunoprin. It has many applications in
Global Thalidomide Market to Witness Robust Expansion by 2022
Worldwide Market Reports added Latest Research Report titled ” Global Thalidomide Market Research Report 2017 ” to its Large Report database. In this report, the global Thalidomide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue
Global Thalidomide Market 2018-2023 Pfizer, Allergan, Acceleron Pharma
Thalidomide Market Research 2018 A market study "Global Thalidomide Market" examines the performance of the Thalidomide market 2018. It encloses an in-depth Research of the Thalidomide market state and the competitive landscape globally. This report analyzes the potential of Thalidomide market in the present and the future prospects from various angles in detail. The Global Thalidomide Market 2018 report includes Thalidomide market Revenue, market Share, Thalidomide industry volume, market Trends, Thalidomide Growth
Thalidomide Market Set for Rapid Growth and Trend, by 2022
Market Study Report delivers significant information and realistic data of the Thalidomide Market. The report presents a deep study of the market growth factors and drivers. In-depth research of the Thalidomide Market limitations and the opportunities enable the user to make the future projection. This Thalidomide Market report values the industry in USD million terms for 2016, expected USD million value by the end of 2022 is provided, showing a steady